Pak-Ming Fong

Dr. Pak-Ming Fong

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
HIHo Ting Venice Iu
Ho Ting Venice Iu
PFPak-Ming Fong
Pak-Ming Fong
HYHin-Cheung-Bill Yam
Hin-Cheung-Bill Yam
PGPeng GAO
Peng GAO
Bingpeng YANBingpeng YAN
Bingpeng YAN
RKRichard Yi-Tsun KAO
Richard Yi-Tsun KAO
Antibiotic tolerance poses a threat to current antimicrobial armamentarium. Bacteria at a tolerant state survive in the presence of antibiotic treatment and account for persistence, relapse and recalcitrance of infections. Antibiotic treatment failure may occur due to antibiotic tolerance. Persistent infections are difficult to treat and are often associated with poor prognosis, imposing an enormous burden on the healthcare system. Effective strategies targeting antibiotic-tolerant bacteria are therefore highly warranted. In this study, small molecule compound SA-558 was identified to be effective against Staphylococcus aureus that are tolerant to being killed by conventional antibiotics. SA-558 mediated electroneutral transport across the membrane and led to increased ATP and ROS generation, resulting in a reduction of the population of antibiotic-tolerant bacteria. In a murine chronic infection model, of which vancomycin treatment failed, we demonstrated that SA-558 alone and in combination with vancomycin caused significant reduction of MRSA abundance. Our results indicate that SA-558 monotherapy or combinatorial therapy with vancomycin is an option for managing persistent S. aureus bacteremia infection and corroborate that bacterial metabolism is an important target for counteracting antibiotic tolerance.

24 June 2026 in bioRxiv
Verified
Preprint
Open access
PFPak-Ming Fong
Pak-Ming Fong
AWAnna I Weaver
Anna I Weaver
AMAbigail L Manson
Abigail L Manson
YPYoungseon Park
Youngseon Park
AEAshlee M Earl
Ashlee M Earl
SWSuzanne Walker
Suzanne Walker
UDP-N-acetylglucosamine (UDP-GlcNAc) is an essential metabolite used to build the peptidoglycan cell wall that protects bacteria against lysis caused by high turgor pressure. More than thirty years ago GlmU, which contains both acetyltransferase and uridyltransferase activities, was discovered to make UDP-GlcNAc in E. coli, and it is now widely considered essential for UDP-GlcNAc synthesis across bacteria. Here we report that the clinically important pathogen Staphylococcus aureus relies on a previously uncharacterized uridyltransferase called NagU to synthesize most of its UDP-GlcNAc for cell wall synthesis. We also report that NagU binds to and negatively regulates DacA, the diadenylate cyclase that makes the essential second messenger cyclic di-AMP, which regulates turgor pressure. We propose a model in which increasing NagU expression simultaneously increases flux into peptidoglycan and increases turgor pressure to enable cell wall expansion. Finally, an evolutionary analysis shows that many bacteria beyond Staphylococcaceae encode NagU homologues but lack GlmU either entirely or in part, suggesting that alternative UDP-GlcNAc biosynthesis pathways are not rare.